Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3, Pivotal, Multicentre, Randomised, Double-blind Controlled Study to Evaluate the Efficacy and Safety of Autologous Osteoblastic Cells (PREOB®) Implantation in Early Stage Non Traumatic Osteonecrosis of the Femoral Head

NCT01529008 is registered in ClinicalTrials.gov with Bone Therapeutics S.A as lead sponsor.

NCT NCT01529008
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01529008 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3, Pivotal, Multicentre, Randomised, Double-blind Controlled Study to Evaluate the Efficacy and Safety of Autologous Osteoblastic Cells (PREOB®) Implantation in Early Stage Non Traumatic Osteonecrosis of the Femoral Head
Lead sponsor
Bone Therapeutics S.A
Phase
Phase 3
Overall status
Terminated
Start date
November 30, 2011
Completion date
November 30, 2018
Enrollment
68 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

osteonecrosis of the femoral head